These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9598656)

  • 21. [Therapeutic effects of intrarectal administration of oxybutynin].
    Radziszewski P; Borkowski A
    Wiad Lek; 2002; 55(11-12):691-8. PubMed ID: 12715351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships.
    Gupta SK; Sathyan G; Lindemulder EA; Ho PL; Sheiner LB; Aarons L
    Clin Pharmacol Ther; 1999 Jun; 65(6):672-84. PubMed ID: 10391673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of Ditropan in the elderly: nursing responsibilities.
    Anderson CL
    Perspectives; 1993; 17(3):11. PubMed ID: 8116314
    [No Abstract]   [Full Text] [Related]  

  • 24. Can oxybutynin cause peripheral neuropathy?
    Patel HR; Albehussi S; Arya M; Miller RA
    J Urol; 2002 Aug; 168(2):646. PubMed ID: 12131334
    [No Abstract]   [Full Text] [Related]  

  • 25. Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis.
    Schulte-Baukloh H; Mürtz G; Henne T; Michael T; Miller K; Knispel HH
    BJU Int; 2006 Feb; 97(2):355-8. PubMed ID: 16430646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Intravesical drug therapy in women with severe urge incontinence. Clinical experiences from a department of gynecology].
    Johansen JK; Lose G
    Ugeskr Laeger; 1999 Nov; 161(44):6052-5. PubMed ID: 10778341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preliminary evaluation of a new controlled-release oxybutynin in urinary incontinence.
    Radomski SB; Caley B; Reiz JL; Miceli PC; Harsanyi Z; Darke AC
    Curr Med Res Opin; 2004; 20(2):249-53. PubMed ID: 15006020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistence with overactive bladder pharmacotherapy in a Medicaid population.
    Shaya FT; Blume S; Gu A; Zyczynski T; Jumadilova Z
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S121-9. PubMed ID: 16161385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cutaneous administration rather than swallowing].
    Schubert-Zsilavecz M
    Krankenpfl J; 2005; 43(7-10):186. PubMed ID: 16515258
    [No Abstract]   [Full Text] [Related]  

  • 30. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?
    Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M
    Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe Xerostomia Secondary to Anticholinergic Drug Therapy: Case Report.
    Brown RS; Rhodes BH; Siewe MS; Matthews TJ
    Dent Today; 2017 Feb; 36(2):136-8. PubMed ID: 29235767
    [No Abstract]   [Full Text] [Related]  

  • 32. Oxybutynin dependence: a case presentation.
    Mutlu EA
    Turk Psikiyatri Derg; 2011; 22(2):131-2. PubMed ID: 21780343
    [No Abstract]   [Full Text] [Related]  

  • 33. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial.
    Leung DY; Kwong YY; Lam DS
    Br J Clin Pharmacol; 2005 Dec; 60(6):668; author reply 669. PubMed ID: 16305595
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
    Schaefer W
    Int J Urol; 2007 Jul; 14(7):670; author reply 670-1. PubMed ID: 17645621
    [No Abstract]   [Full Text] [Related]  

  • 35. Severe anticholinergic drug-induced delirium in a young adult after renal transplantation.
    Götz AK; Reinhold SW; Szecsey A; Banas B; Krämer BK
    Transpl Int; 2009 Feb; 22(2):249-50. PubMed ID: 18786150
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment can lead to a long dry spell.
    Starr CH
    Bus Health; 2002; Spec No():15-9, 24. PubMed ID: 11974567
    [No Abstract]   [Full Text] [Related]  

  • 37. [Detrusor instability--an important but underestimated factor in urinary incontinence in women].
    Dimitrov R; Doganov N
    Akush Ginekol (Sofiia); 1998; 37(3):23-6. PubMed ID: 10204261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transdermal oxybutynin: sticking to the facts.
    Cartwright R; Cardozo L
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Case profile: anticholinergic-induced hydronephrosis.
    Novicki DE; Willscher MK
    Urology; 1979 Mar; 13(3):324-5. PubMed ID: 442360
    [No Abstract]   [Full Text] [Related]  

  • 40. Epistaxis as a side effect of oxybutynin in children: report of two cases.
    Batista JE; Caffaratti J; Garat JM
    Neurourol Urodyn; 1994; 13(1):85-6. PubMed ID: 8156079
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.